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AbstrACt
Objective to compare the 10-year outcome (disease 
activity, disability, mortality) of two cohorts of patients 
with inflammatory polyarthritis (Ip) recruited 10 years 
apart.
Methods patients with Ip were recruited to the norfolk 
Arthritis register from 1990 to 1994 (cohort 1 (C1)) 
and from 2000 to 2004 (cohort 2 (C2)). demographic 
and clinical data were collected at baseline and at 
years 1, 2, 3, 5, 7 and 10. Longitudinal disease activity 
(swollen/tender 51 joint counts (SJC51/tJC51)) and 
disability (Health Assessment Questionnaire (HAQ)) were 
compared between the cohorts using population-average 
negative binomial regression and generalised estimating 
equation analysis, respectively. risk of 10-year mortality 
was compared between cohorts using Cox models. risk 
of cardiovascular disease (CVd) mortality was compared 
between cohorts using competing risks analysis. 
Mortality rate ratios (Mrr), adjusted for changes in 
mortality risk of the general population, were calculated 
using poisson regression.
results In total 1653 patients were recruited 
(C1=1022, C2=631). patients in C2 had 17% lower 
SJC51 than C1 over 10 years (95% CI −23% to −10%), 
whereas tJC51 and HAQ were comparable. C2 patients 
had reduced risk of all-cause and CVd mortality 
compared with C1 (all-cause: Hr 0.72, 95% CI 0.56 to 
0.95; CVd: subhazard ratio 0.58, 95% CI 0.37 to 0.93). 
After accounting for changes in mortality risk in the 
general population, the difference in mortality was non-
significant (all-cause: Mrr 0.78, 95% CI 0.56 to 1.10; 
CVd: Mrr 0.77, 95% CI 0.48 to 1.24).
Conclusion disease activity significantly improved in 
the new millennium, whereas disability and mortality 
were unchanged.
Inflammatory polyarthritis (IP) and its subset rheu-
matoid arthritis (RA) are chronic conditions associ-
ated with synovial joint inflammation, progressive 
joint damage and premature mortality.1 2 However 
outcomes can be improved by administration of 
appropriate therapy.3 4 There have been significant 
advances in the available therapies to treat RA over 
the past two decades. Methotrexate was introduced 
as a treatment for RA in the 1990s and became the 
first-choice synthetic disease-modifying antirheu-
matic drug (sDMARD).5 6 Since then biologic agents 
(biologic disease-modifying antirheumatic drugs 
(bDMARDs)) have been introduced and proven 
to be effective, but costly and are generally not 
used as first-line therapy.7 8 Furthermore there has 
been a philosophical shift towards treating patients 
early after symptom onset, which is associated with 
improved physical function9–11 and radiographic 
damage.4 12 13
A number of studies have compared patients 
during and post the treatment changes of the 
mid-1990s. An analysis of the Nijmegen early RA 
cohort compared the 5-year outcome of three 
subcohorts, based on the time period patients were 
recruited (subcohort 1=1985–1990, subcohort 
2=1990–1995, subcohort 3=1995–2000). Patients 
in subcohort 3 had significantly lower mean Disease 
Activity Score (DAS28) at year 5 compared with the 
other two cohorts (mean DAS28: subcohort 1=3.7, 
subcohort 2=3.4, subcohort 3=3.2). However 
the Health Assessment Questionnaire (HAQ) scores 
were higher at year 5 in the most recent subcohort, 
although this was not statistically significant (mean 
HAQ: subcohort 1=0.49, subcohort 2=0.44, 
subcohort 3=0.83).14 Humphreys et al compared 
mortality rates during the first 7 years of follow-up 
of three cohorts of patients with early RA recruited 
to the Norfolk Arthritis Register (NOAR) (cohort 
1=1990–1994, cohort 2=1995–1999, cohort 
3=2000–2004). That analysis reported no signifi-
cant differences between the mortality rates in each 
of these cohorts over 7 years of follow-up (mortality 
rate ratio (MRR): cohort 1=ref, cohort 2=1.13 
(95% CI 0.84 to 1.52), cohort 3=1.00 (95% CI 
0.70 to 1.43)).15
The natural history of IP and RA is becoming 
less severe16 17; therefore, it is difficult to infer 
whether any improvements in long-term outcome 
(ie, 10 years) are associated with less severe disease 
or with the changes in treatment strategy. Thus 
the aim of this study was to compare the 10-year 
outcome of two cohorts of patients recruited 10 
years apart, controlling for disease severity of the 
cohorts at baseline. Specifically, the objectives were 
to compare the baseline and 10-year characteris-
tics of two cohorts of patients, one recruited from 
1990 to 1994 and the other from 2000 to 2004, 
then to compare the disease activity, disability and 
mortality of the two cohorts over the course of 10 
years.
to cite: Gwinnutt JM, 
Symmons dpM, 
MacGregor AJ, et al. 
Ann Rheum Dis Epub ahead 
of print: [please include day 
Month Year]. doi:10.1136/
annrheumdis-2017-212426
Handling editor Josef S 
Smolen
 ► Additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2017- 212426).
1Arthritis research UK Centre 
for Epidemiology, Centre for 
Musculoskeletal research, 
division of Musculoskeletal and 
dermatological Sciences, School 
of Biological Sciences, Faculty of 
Biology, Medicine and Health, 
University of Manchester, 
Manchester Academic Health 
Science Centre, Manchester, UK
2rheumatology department, 
norfolk and norwich University 
Hospitals nHS trust, norwich, 
UK
3norwich Medical School, 
University of East Anglia 
Faculty of Medicine and Health 
Sciences, norwich, UK
4nIHr Manchester Biomedical 
research Centre, Central 
Manchester University 
Hospitals nHS Foundation trust, 
Manchester Academic Health 
Science Centre, Manchester, UK
Correspondence to
dr Suzanne M M Verstappen, 
Arthritis research UK 
Epidemiology Unit, University of 
Manchester, Manchester M13 
9pt, UK;  
 Suzanne. Verstappen@ 
manchester. ac. uk
received 22 September 2017
Accepted 25 January 2018
 ARD Online First, published on February 23, 2018 as 10.1136/annrheumdis-2017-212426
Copyright Article author (or their employer) 2018. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
group.bmj.com on March 2, 2018 - Published by http://ard.bmj.com/Downloaded from 
2 Gwinnutt JM, et al. Ann Rheum Dis 2018;0:1–7. doi:10.1136/annrheumdis-2017-212426
Clinical and epidemiological research
PAtients And MetHOds
The NOAR began recruiting patients with IP registered with a 
primary care physician (general practitioner (GP)) in the former 
Norwich Health Authority region, Norfolk, UK in 1990. Inci-
dent cases of IP were recruited from GPs or rheumatologists. 
The inclusion criteria were ≥16 years old and ≥2 swollen joints 
lasting ≥4 weeks. In this study we included patients recruited 
from 1990 to 1994 (cohort 1) and those recruited from 2000 
to 2004 (cohort 2). Patients were excluded from this analysis 
if their baseline assessment took place >2 years after symptom 
onset. Patients were also excluded if they were subsequently 
diagnosed with a condition other than RA, psoriatic arthritis, 
postviral arthritis or undifferentiated arthritis. Patients gave 
written informed consent. More details about NOAR can be 
found elsewhere.18
Assessments
Patients were assessed at baseline and at 1, 2, 3, 5, 7 and 10 years 
thereafter. Patients were only assessed beyond year 5 if they had 
documented swollen joints on two or more occasions or had 
received disease-modifying antirheumatic drugs (DMARDs) or 
oral corticosteroids by the fifth year assessment. Demographics 
were collected at baseline. A research nurse performed a 51 
swollen and tender joint count (SJC51/TJC51), from which 28 
joint counts were derived. Blood samples were taken at baseline, 
separated and frozen for future analysis. C reactive protein level 
(CRP; mg/L), rheumatoid factor positivity (RF; latex test, posi-
tive cut-off 40 units/mL) and anticyclic citrullinated peptide anti-
body positivity (anti-CCP2; tested using the Axis-Shield Diastat 
Anti-CCP Kit, Dundee, UK; cut-off 5 units/mL) were deter-
mined from these samples. The three-component DAS28-CRP 
was calculated.19 The 2010 American College of Rheumatology 
(ACR)/European League Against Rheumatism (EULAR) criteria 
for RA were applied retrospectively to the baseline character-
istics of the patients.20 Patients reported smoking status, and 
the start and stop dates for all sDMARDs, bDMARDs and oral 
steroids at each assessment.
Outcomes
Disease activity was assessed using SJC51 and TJC51 at each 
assessment, other than assessments 5 and 7 at which joint counts 
were not performed. Disability was self-reported at each assess-
ment using the HAQ adapted for British use.21 This is a vali-
dated self-report measure of functional disability that yields a 
score from 0 (no disability) to 3 (maximum disability). Patients 
were flagged with the Office for National Statistics (ONS), who 
provided copies of death certificates as patients died, including 
date and cause of death, coded using the International Classifica-
tion of Diseases (ICD) V.9 and V.10. ICD9 codes were recoded to 
the corresponding ICD10 codes. Initially all-cause mortality was 
assessed, before assessing death from cancer (ICD10 codes C00–
D48), cardiovascular disease (CVD; ICD10 codes I00–I99) or 
respiratory disease (ICD10 codes J00–J99) as the underlying cause 
of death. For mortality analysis patients were censored 10 years 
after symptom onset or on emigration from the country (n=7). 
Due to ONS flagging, mortality data were complete, regardless 
of whether patients stopped attending follow-up assessments. 
The ONS also provided age-specific and sex-specific all-cause 
and CVD specific mortality rates by calendar year for the Norfolk 
population (1990–2013) (online supplementary table 1).
statistical analysis
The baseline and 10-year demographic, clinical and treatment 
characteristics of each cohort were summarised using descriptive 
statistics. Quantile, logistic or negative binomial regression 
was used to compare the baseline and 10-year scores between 
cohorts, depending on the type and distribution of the data. Age 
at symptom onset and gender were controlled for initially; then 
other baseline variables were included in the tenth year outcome 
models (age, gender, symptom duration at baseline, smoking 
status, SJC51, TJC51, RF, anti-CCP2, CRP, HAQ score and 
being on sDMARDs/steroids).
To analyse longitudinal disease activity and disability, 
the median SJC51, TJC51 and HAQ scores over 10 years are 
displayed using fractional polynomial smoothed plots. Popula-
tion-average negative binomial regression was used to compare 
the SJC51 and TJC51 of the two cohorts over the repeated 
measures. HAQ scores were compared between cohorts over 
follow-up using generalised estimating equation analysis using 
the identity link function. All models were initially adjusted for 
baseline age and gender, before controlling for other baseline 
characteristics (listed above). Time-varying smoking status was 
then included in the model to control for differences in prevalence 
of smoking between the cohorts. Lastly, time-varying DMARD 
and steroid exposure were included to assess whether differences 
in medication usage between the two cohorts accounted for any 
difference in the outcomes. To analyse mortality, Kaplan-Meier 
survival curves were plotted. A Cox proportional hazards model 
was used to compare the risk of mortality between cohorts, 
with the same adjustments made as above. The proportional 
hazards assumption was met. An MRR was calculated using 
Poisson regression, which allows comparisons of mortality rates 
between cohorts, adjusted for the background age-specific and 
gender-specific mortality rates of the Norfolk population. This 
model was initially adjusted for baseline age and gender, before 
adjusting for further baseline characteristics (see above). For this 
analysis, patients were censored after 10 years of follow-up or at 
the end of 2013, whichever came first. To analyse risk of specific 
causes of death, competing risks regression analyses were applied, 
with each of the three causes of death (cancer, CVD, respiratory 
disease) as the outcome of interest in turn, with competing risks 
being other causes of death.22 An MRR was also calculated for 
CVD mortality, using the same methods as above.
Multiple imputation using iterative chained equations was 
used to account for missing data at assessments which patients 
attended. Imputed variables were only used as covariates in 
regression analyses. In sensitivity analysis, we restricted the anal-
yses to those patients fulfilling the 2010 criteria for RA at base-
line (n=961). All analyses were performed using Stata V.13.1.
results
In total 1653 patients were included in this study: 1022 patients 
in cohort 1 and 631 in cohort 2 (table 1). Patients in cohort 2 
were older at symptom onset and had longer symptom duration 
at baseline (median (IQR) age (years): cohort 1=54 (41–67), 
cohort 2=58 (47–70), median difference=4 (95% CI 2 to 6); 
median (IQR) symptom duration (months): cohort 1=5.1 (2.7–
9.4), cohort 2=6.6 (3.9–11.3), median difference=1.5 (95% CI 
0.9 to 2.2)). Cohort 2 had lower SJC51 and TJC51 at baseline 
(median (IQR) SJC51: cohort 1=6 (2–13), cohort 2=3 (1–8), 
relative difference=−40% (95% CI −46% to −33%); median 
(IQR) TJC51: cohort 1=7 (3–16), cohort 2=4 (1–12), rela-
tive difference −25% (95% CI −33% to −16%)). However, a 
greater proportion of patients in cohort 2 were on sDMARDs 
at the time of the baseline assessment (n (%) on sDMARDs at 
baseline: cohort 1=153 (15.0%), cohort 2=278 (44.1%), OR 
4.47 (95% CI 3.54 to 5.65)). Nevertheless patients in cohort 2 
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had higher functional disability at baseline (median (IQR) HAQ 
score: cohort 1=0.75 (0.25–1.38), cohort 2=0.88 (0.38–1.63), 
median difference=0.13 (95% CI 0.01 to 0.24)) (see online 
supplementary table 2 for the baseline characteristics of patients 
with RA).
Cross-sectional analysis at 10 years
In total 947 (57.3%) patients attended the tenth year assess-
ment (cohort 1=607 (59.4%), cohort 2=340 (53.8%)) (table 2) 
(see online supplementary table 3 for summary statistics 
regarding the reasons why patients left the cohort). Patients in 
cohort 2 had lower SJC51 (median (IQR) SJC51: cohort 1=1 
(0–4), cohort 2=0.5 (0–2.5)) compared with cohort 1. After 
controlling for baseline characteristics, patients in cohort 2 had 
33% lower SJC51 compared with cohort 1 at 10 years (95% CI 
−47% to −15%). The median TJC51 at 10 years were compa-
rable between cohorts, while cohort 2 had a slightly higher 
median HAQ score; after adjusting for baseline characteristics, 
table 1 Baseline characteristics of patients with inflammatory polyarthritis included in the analysis, stratified by cohort
Cohort 1 (1990–1994) Cohort 2 (2000–2004) Median difference/Or/ relative 
difference (95% Ci)*n Median (iQr) n Median (iQr)
Age at symptom onset (years) 1022 54 (41–67) 631 58 (47–70) 4.00 (2.00 to 6.00)
Gender (n (%) female) 662 (64.8) 408 (64.7) OR 0.99 (0.81 to 1.22)
Smoking status 1021 569 
  Never, n (%) 323 (31.6) 181 (31.8) 
  Ex-smoker, n (%) 424 (41.5) 245 (43.1) RRR 1.03 (0.81 to 1.31) 
  Current smoker, n (%) 274 (26.8) 143 (25.1) RRR 0.93 (0.71 to 1.22)† 
Symptom duration (months) 1022 5.1 (2.7–9.4) 631 6.6 (3.9–11.3) 1.54 (0.89 to 2.18)
Swollen joint counts 
  28 1022 5 (1–11) 631 2 (0–6) − 39% (−45% to −31%) 
  51 1022 6 (2–13) 631 3 (1–8) − 40% (−46% to −33%) 
Tender joints counts 
  28 1022 5 (2–12) 631 2 (0–8) −29% (−37% to −20%) 
  51 1022 7 (3–16) 631 4 (1–12) − 25% (−33% to −16%) 
CRP (mg/L) 817 5 (0–16) 521 9.5 (3–22) 4.50 (2.87 to 6.13)
DAS28-CRP 817 3.95 (2.88–5.02) 521 3.60 (2.65–4.53) −0.35 (−0.56 to −0.15)
HAQ 1010 0.75 (0.25–1.38) 616 0.88 (0.38–1.63) 0.13 (0.01 to 0.24)
RF status 891 553 
  Positive, n (%) 252 (28.3) 201 (36.4) OR 1.45 (1.15 to 1.82) 
Anti-CCP2 status 759 511 
  Positive, n (%) 178 (23.5) 161 (31.5) OR 1.50 (1.17 to 1.93) 
Met 2010 RA criteria, n (%) 614 (60.1) 347 (55.0) OR 0.81 (0.66 to 0.99)
Current sDMARDs use, n (%) 153 (15.0) 278 (44.1) OR 4.47 (3.54 to 5.65)
Treatment delay, months 565 9 (4–22) 471 6 (3–12) −3.2 (−4.6 to –1.9)
*Quantile/logistic/negative binomial regression was used to compare the two cohorts on each variable depending on the type of variable. Cohort 1 is the reference category.
†Multinomial logistic regression used to compare smoking status between cohorts. Never smoking is the base outcome and cohort 1 is the reference category.
anti-CCP2, anticyclic citrullinated protein antibodies; CRP, C reactive protein; DAS28, Disease Activity Score (28); HAQ, Health Assessment Questionnaire; n, number of patients 
with available data; RA, rheumatoid arthritis; RF, rheumatoid factor; RRR, relative risk ratio; sDMARD, synthetic disease-modifying antirheumatic drugs.
table 2 Characteristics at 10 years and median change from baseline, stratified by cohort
Cohort 1 (1990–1994) Cohort 2 (2000–2004) Median difference/
Or/relative difference 
(95% Ci)*
Median difference/
Or/ relative difference 
(95% Ci)†n Median (iQr) n Median (iQr)
Age at 10-year assessment (years) 607 62 (51–72) 340 66 (56–75) 4.00 (1.55 to 6.45) – 
Gender (n (%) female) 422 (69.5) 238 (70.0) OR 1.02 (0.77 to 1.37) – 
Swollen joint counts (51) 601 1 (0–4) 340 0.5 (0.0–2.5) −36% (−49% to −20%) −33% (−47% to −15%) 
  Median change from baseline 601 −4 (−10 –−1) 340 −2 (−6– 0)
Tender joints counts (51) 601 2 (0–11) 340 2 (0–8) −5% (−24% to 19%) 2% (−20% to 30%) 
  Median change from baseline 601 −3 (−11–1) 340 −1 (−6–2)
HAQ 597 0.88 (0.25–1.63) 336 1.00 (0.25–1.88) 0.01 (−0.18 to 0.20) −0.01 (−0.16 to 0.14) 
  Median change from baseline 588 0.13 (−0.25–0.75) 330 0.00 (−0.38–0.63)
Current sDMARDs use, n (%) 195 (32.1) 209 (61.5) OR 3.35 (2.53 to 4.43) OR 2.71 (1.91 to 3.86)
*Quantile/logistic/negative binomial regression was used to compare the two cohorts on each variable depending on the type of variable. Regressions comparing SJC, TJC, HAQ 
and current DMARD use between cohorts controlled for age and gender. Cohort 1 is the reference category. 
†Quantile/logistic/negative binomial regression used to compare SJC, TJC, HAQ and number on sDMARDs between cohorts at 10 years. These models controlled for baseline: age, 
gender, symptom duration before baseline, smoking status, SJC (51), TJC (51), RF, anti-CCP, CRP, HAQ score and being on sDMARDs/steroids. Cohort 1 is the reference category.
anti-CCP2, anticyclic citrullinated protein antibodies; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; n, number 
of patients with available data; sDMARD, synthetic disease-modifying antirheumatic drug; SJC, swollen joint count; TJC, tender joint count.
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the differences were not statistically significant (median (IQR) 
TJC51: cohort 1=2 (0–11), cohort 2=2 (0–8), relative differ-
ence 2% (95% CI −20% to 30%); median (IQR) HAQ: cohort 
1=0.88 (0.25–1.63), cohort 2=1.00 (0.25–1.88), median differ-
ence −0.01 (−0.16 to 0.14)) (table 2). Similar results were seen 
when restricting the results to patients with RA who met the 
2010 ACR/EULAR criteria (online supplementary table 4).
longitudinal analysis over 10 years
Consistently more patients in cohort 2 were taking sDMARDs 
at each follow-up than cohort 1 (table 3). Oral steroid use was 
also consistently higher in cohort 2 compared with cohort 1. 
Very few patients in cohort 1 took bDMARDs at any time point 
as many would have reached their tenth anniversary assessment 
before bDMARDs were available, whereas 11.8% of patients in 
cohort 2 were taking bDMARDs at the tenth year follow-up. 
Data restricted to patients with RA only are shown in online 
supplementary table 5.
Figure 1A,B shows the unadjusted median SJC51 and TJC51 
over the course of 10 years, stratified by cohort. Patients in 
cohort 2 had consistently lower median SJC51 over the course 
of 10 years and had lower median TJC51 at all follow-ups other 
than at follow-up 10, at which median TJC51 were comparable. 
Patients in cohort 2 had, on average, 17% lower SJC51 over 
10 years than patients in cohort 1, after adjusting for baseline 
characteristics (relative difference −17%, 95% CI −23% to 
−10%), whereas TJC51 were comparable between cohorts over 
follow-up (relative difference 1%, 95% CI −7% to 10%). At 
baseline there were 274 current smokers in cohort 1 (26.8%) 
and 143 in cohort 2 (22.7%). Over the course of follow-up, 
78 of these patients quit in cohort 1 (28.5%), whereas 62 quit 
in cohort 2 (43.4%). However, the inclusion of time-varying 
smoking status did not substantially alter the results; the inclu-
sion of time-varying treatment also did not alter the results 
(table 4).
Figure 1C displays the median HAQ score over the course 
of 10 years, stratified by cohort. Patients in cohort 2 had on 
average 0.09 higher HAQ score over follow-up compared with 
cohort 1 (95% CI 0.03 to 0.16), after controlling for age and 
gender. However after controlling for baseline variables, the 
HAQ scores between the cohorts over 10 years were compa-
rable (table 4). The same was true after including time-varying 
smoking and treatment into the model.
During 15 185 person-years of follow-up, 291 patients died 
(cohort 1=179 (17.5%), cohort 2=112 (17.8%)). Figure 1D 
shows the Kaplan-Meier curves for the two cohorts. Patients in 
cohort 2 had reduced risk of mortality compared with cohort 
1 after adjusting for age and gender (HR 0.76, 95% CI 0.60 to 
0.96) and after adjusting for baseline variables (HR 0.72, 95% CI 
0.56 to 0.95). However, there was no significant difference in 
risk of mortality between the cohorts when restricting the anal-
ysis to patients who met the 2010 ACR/EULAR RA criteria at 
baseline (table 4). Including time-varying smoking and treatment 
into the model did not substantially alter the results (HR 0.77, 
95% CI 0.58 to 1.02). The MRR for cohort 2 compared with 
cohort 1 was 0.96 (95% CI 0.75 to 1.22) after adjusting for age 
and gender. After further adjustment, the MRR was 0.78 (95% 
CI 0.56 to 1.10), indicating no significant difference in mortality 
table 3 Number and percentage of patients at each follow-up on different treatments and smoking status, stratified by cohort
Follow-up assessment
0 1 2 3 5 7 10
Patients at assessment
  Cohort 1, n 1022 948 875 832 780 626 607
  Cohort 2, n 631 588 530 533 498 407 340
Smoking status
Cohort 1
  Never, n (%) 323 (31.6) 302 (31.9) 281 (32.1) 265 (31.9) 252 (32.3) 204 (32.6) 193 (31.8)
  Ex-smoker, n (%) 424 (41.5) 416 (43.9) 392 (44.8) 385 (46.4) 361 (46.3) 288 (46.0) 287 (47.3)
  Current, n (%) 274 (26.8) 229 (24.2) 202 (23.1) 180 (21.7) 167 (21.4) 134 (21.4) 127 (20.9)
Cohort 2
  Never, n (%) 233 (37.1) 218 (37.2) 201 (38.1) 203 (38.2) 195 (39.2) 157 (38.7) 134 (39.5)
  Ex-smoker, n (%) 252 (40.1) 244 (41.6) 225 (42.6) 231 (43.5) 211 (42.5) 186 (45.8) 161 (47.5)
  Current, n (%) 143 (22.7) 124 (21.2) 102 (19.3) 97 (18.3) 91 (18.3) 63 (15.5) 44 (12.9)
sDMARD*
  Cohort 1, n (%) 153 (15.0) 276 (29.1) 274 (31.3) 269 (32.3) 239 (30.6) 207 (33.1) 195 (32.1)
  Cohort 2, n (%) 278 (44.1) 356 (60.5) 327 (61.7) 321 (60.2) 288 (57.8) 256 (62.9) 209 (61.5)
Methotrexate
  Cohort 1, n (%) 12 (1.2) 56 (5.9) 73 (8.3) 93 (11.2) 116 (14.9) 120 (19.8) 129 (21.3)
  Cohort 2, n (%) 186 (29.5) 251 (42.7) 231 (43.6) 231 (43.3) 209 (42.0) 196 (48.2) 163 (47.9)
bDMARD*
  Cohort 1, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 11 (1.8)
  Cohort 2, n (%) 2 (0.3) 5 (0.9) 17 (3.2) 19 (3.6) 27 (5.4) 29 (7.1) 40 (11.8)
Oral steroids
  Cohort 1, n (%) 78 (7.6) 113 (11.9) 109 (12.5) 111 (13.3) 93 (11.9) 70 (11.2) 66 (10.9)
  Cohort 2, n (%) 132 (20.9) 124 (21.1) 96 (18.1) 91 (17.1) 83 (16.7) 63 (15.5) 39 (11.5)
Percentages are given as a percentage of the number of patients in the corresponding cohort at the corresponding follow-up. 
*sDMARDs included intramuscular gold salts, penicillamine, sulfasalazine, (hydroxy)chloroquine, methotrexate, azathioprine, cyclophosphamide and leflunomide. bDMARDs 
included etanercept, infliximab, adalimumab and rituximab. 
bDMARD, biologic disease-modifying antirheumatic drug; sDMARD, synthetic disease-modifying antirheumatic drug. 
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in cohort 2 after accounting for differences in the background 
risk of death between the cohorts.
The proportion of patients dying from CVD was lower 
in cohort 2 than in cohort 1 (CVD n (% total died): cohort 
1=72 (40.2%), cohort 2=34 (30.4%)), and this was statisti-
cally significant, after adjusting for age and gender (subhazard 
ratio (SHR) 0.61, 95% CI 0.40 to 0.93) and after adjusting for 
baseline variables (SHR 0.58, 95% CI 0.37 to 0.93). Adjust-
ment for time-varying smoking and time-varying treatment did 
not substantially alter the estimate (SHR 0.61 (95% CI 0.37 to 
0.99)). The MRR for CVD mortality was 0.90 (95% CI 0.59, 
1.37) when adjusting for age and gender. After further adjust-
ment, the MRR was 0.77 (95% CI 0.48 to 1.24), indicating no 
significant difference in CVD mortality in cohort 2 compared 
with cohort 1, over the secular change of background risk of 
CVD mortality in the general population. The proportions of 
patients dying from cancer and respiratory disease were slightly 
higher in cohort 2 (cancer, n (% total died): cohort 1=53 
(29.6%), cohort 2=38 (33.9%); respiratory disease, n (% total 
died): cohort 1=22 (12.3%), cohort 2=21 (18.7%)), and the 
risk of death from these causes was not significantly different 
between the two cohorts (table 4).
disCussiOn
This analysis shows that patients with early IP with symptom 
onset in the new millennium had lower 10-year mortality risk 
than patients with symptom onset 10 years earlier. However, 
after controlling for the background mortality risk in the general 
population, the difference in mortality risk between the cohorts 
was non-significant. In addition, SJCs were significantly lower in 
patients with IP in cohort 2 compared with cohort 1. However, 
TJC and disability over 10 years were not improved for patients 
in cohort 2 compared with cohort 1.
A meta-analysis of 11 longitudinal studies of patients with RA 
reported decreasing mortality rate from 1955 to 1995.23 Further-
more, a recent analysis of data from 31 countries assessing 
mortality with RA as the underlying cause reported a reduction 
in mortality rates over the period between 1987 and 2011 (mean 
pooled age-standardised rate: 1987–1989=7.1/million person-
years, 2009–2011=3.7/million person-years).24 However, our 
analysis did not demonstrate a significant reduction in 10-year 
mortality in patients with early IP, after accounting for secular 
changes in the background mortality risk of the general popula-
tion. Our results are in line with a study of patients with RA from 
Ontario, Canada, which reported no significant change in MRR 
over the period 1996–2009.25
A recent analysis from a cohort of patients recruited in 
Olmsted County, Minnesota, reported a reduction in CVD 
mortality over a 10-year period for patients recruited from 
2000 to 2007 compared with patients recruited from 1990 to 
1999.26 While the effect estimate from our analysis illustrated a 
reduction in CVD mortality, the CI overlapped 1, meaning our 
analysis cannot confirm the conclusions of the Olmsted County 
study.
The results of the disease activity and disability analyses extend 
previous literature looking at outcome of patients over 5 years.14 
However, our analysis is the first study to directly compare the 
longitudinal clinical outcome over 10 years between two cohorts 
of patients recruited 10 years apart. Including treatment variables 
as covariates tempered the association between cohort inclusion 
and long-term disability and SJC51, but disability remained 
comparable between cohorts and SJC51 remained significantly 
lower for cohort 2 compared with cohort 1. While this suggests 
that there may be factors other than treatment influencing the 
association between cohort and outcome, it is possible that 
there is residual confounding by treatment given and treatment 
response as we were only able to adjust for whether or not the 
patient was on a DMARD at each assessment.
Different patterns of device usage between the cohorts could be 
influencing the HAQ scores. However, recalculating the HAQ to 
remove the device adjustment did not alter the results (data not 
shown). An explanation for why there were no improvements 
Figure 1 Outcome over 10 years stratified by cohort: (A) median swollen joint count 51, (B) median tender joint count 51, (C) median Health 
Assessment Questionnaire (HAQ) score and (D) Kaplan-Meier survival curve (adjusted for age and gender (age centred at 70 years)).
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in ‘subjective’ outcomes (TJC, HAQ) could be that the expec-
tation of treatment efficacy was higher in patients in cohort 2 
compared with cohort 1. Thus a similar level of disability may 
be rated as higher in cohort 2 compared with cohort 1.27 A qual-
itative study published in 2004 reported that some patients had 
very high expectations of the efficacy of treatment,28 and expec-
tations of patients have been demonstrated to be associated with 
differences in pain following joint replacement surgery29 30 and 
adherence to medication.31
This study has a number of strengths. The continuous 
recruitment and standardised assessment of patients in NOAR 
over 20 years meant that we were able to compare the long-
term outcomes of patients treated in different treatment 
eras. Adjusting for the baseline characteristics of the patients 
controlled for the secular change towards reduced severity of IP 
and RA at presentation.16 17 As with any study following patients 
over an extended period, there was attrition in both cohorts. 
However the characteristics of the patients leaving the study did 
not differ between cohorts, and therefore attrition is not biasing 
the analysis. Furthermore, as sDMARD dose was not routinely 
collected for these cohorts, we were unable to analyse changes 
in dose over follow-up.
In conclusion we have shown a 17% reduction in SJCs in 
patients with more recent symptom onset. However the 10-year 
mortality, TJCs and functional disability of patients did not 
significantly differ between the cohorts.
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